We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+12.59%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$18.9B
AUM Growth
+$3.55B
(+23%)
Cap. Flow
+$2.11B
Cap. Flow
% of AUM
11.15%
Top 10 Holdings %
Top 10 Hldgs %
14.56%
Holding
1,090
New
199
Increased
468
Reduced
192
Closed
179
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$216M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$129M |
| 3 |
Brown & Brown
BRO
|
+$121M |
| 4 |
Arthur J. Gallagher & Co
AJG
|
+$116M |
| 5 |
AKRO
Akero Therapeutics
AKRO
|
+$90.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$144M |
| 2 |
MetLife
MET
|
+$97.2M |
| 3 |
Travelers Companies
TRV
|
+$91.9M |
| 4 |
Electronic Arts
EA
|
+$91.9M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$76M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.08% |
| 2 | Technology | 23.91% |
| 3 | Financials | 10.59% |
| 4 | Consumer Discretionary | 9.42% |
| 5 | Industrials | 7.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KMTS
751
Kestra Medical Technologies
KMTS
$1.41B
| $1.67M | 0.01% |
100,718
| – | – |
|
|
CEPT
752
DELISTED
Cantor Equity Partners II
CEPT
| $1.65M | 0.01% |
+150,000
| New | +$1.69M |
|
753
Woodward
WWD
$21.8B
| $1.63M | 0.01% |
6,633
-4,541
| -41% | -$929K |
|
754
Clorox
CLX
$12.2B
| $1.6M | 0.01% |
13,333
+2,926
| +28% | +$390K |
|
755
Rocket Pharmaceuticals
RCKT
$376M
| $1.6M | 0.01% |
652,865
| – | – |
|
756
Las Vegas Sands
LVS
$30B
| $1.6M | 0.01% |
36,689
+7,657
| +26% | +$298K |
|
757
Denali Therapeutics
DNLI
$3.78B
| $1.59M | 0.01% |
113,517
| – | – |
|
758
Torrid Holdings
CURV
$262M
| $1.55M | 0.01% |
+526,500
| New | +$2.76M |
|
759
CDW
CDW
$19.1B
| $1.54M | 0.01% |
8,635
-255,510
| -97% | -$43.4M |
|
760
Omnicom Group
OMC
$21.7B
| $1.52M | 0.01% |
21,104
+17,784
| +536% | +$1.31M |
|
|
ESPR
761
DELISTED
Esperion Therapeutics
ESPR
| $1.48M | 0.01% |
1,503,754
| – | – |
|
762
Petco
WOOF
$831M
| $1.45M | 0.01% |
513,648
+64,287
| +14% | +$200K |
|
763
Old Dominion Freight Line
ODFL
$44.7B
| $1.43M | 0.01% |
+8,819
| New | +$1.41M |
|
|
JNPR
764
DELISTED
Juniper Networks
JNPR
| $1.43M | 0.01% |
35,814
+7,841
| +28% | +$281K |
|
765
KALA BIO
KALA
$14.6M
| $1.43M | 0.01% |
6,003
+828
| +16% | +$162K |
|
766
Jack Henry & Associates
JKHY
$11.1B
| $1.42M | 0.01% |
7,877
+1,718
| +28% | +$305K |
|
|
ABVX
767
Abivax
ABVX
$10.8B
| $1.41M | 0.01% |
183,800
-18,124
| -9% | -$118K |
|
768
Best Buy
BBY
$17.8B
| $1.4M | 0.01% |
20,838
+4,402
| +27% | +$299K |
|
769
Builders FirstSource
BLDR
$7.91B
| $1.39M | 0.01% |
11,954
+2,231
| +23% | +$257K |
|
|
IPG
770
DELISTED
Interpublic Group of Companies
IPG
| $1.39M | 0.01% |
56,944
-649,929
| -92% | -$15.8M |
|
|
SION
771
Sionna Therapeutics
SION
$2.28B
| $1.39M | 0.01% |
80,000
| – | – |
|
772
Chord Energy
CHRD
$7.73B
| $1.38M | 0.01% |
14,200
-365,845
| -96% | -$34.8M |
|
|
TRML
773
DELISTED
Tourmaline Bio
TRML
| $1.36M | 0.01% |
85,177
-74,909
| -47% | -$1.21M |
|
774
Xenon Pharmaceuticals
XENE
$6.11B
| $1.36M | 0.01% |
+43,380
| New | +$1.42M |
|
775
Aquestive Therapeutics
AQST
$468M
| $1.35M | 0.01% |
407,661
| – | – |
|
Similar funds
PAM
TCIIS
UIM
VAI
Woodline Partners's Q2 2025 Portfolio in Review
As of Q2 2025, Woodline Partners held 1,090 positions worth $18.9B, up 23% from $15.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Woodline Partners deployed $2.11B of net new capital in Q2 2025, opening 199 new positions and adding to 468 existing holdings. Its largest new stake was Brown & Brown: 1,079,076 shares worth $120M.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, down from 30% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $76M trimmed.
- Woodline Partners's largest Q2 2025 buy was Brown & Brown: 1,079,076 shares worth $120M.
- Woodline Partners added most to Microsoft in Q2 2025, an estimated $216M increase.
- Woodline Partners's biggest Q2 2025 reduction was SpringWorks Therapeutics, cutting an estimated $76M.
- Woodline Partners fully exited Lam Research in Q2 2025, selling an estimated $144M.
- Woodline Partners's ten largest holdings make up 15% of its $18.9B portfolio in Q2 2025.
- Woodline Partners opened 199 new positions and closed 179 in Q2 2025.
- Woodline Partners's portfolio value rose 23% quarter-over-quarter to $18.9B.
Based on Woodline Partners's 13F filing for Q2 2025, filed 14 Aug 2025.